Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential impact of Northern Ireland being the only part of the UK without routine access to abiraterone for men with non-metastatic prostate cancer on patient outcomes across the UK.

There are no current plans to hold discussions with the Northern Irish Department of Health or the Health and Social Care Board on abiraterone access in Northern Ireland. Decisions on the availability of medicines in Northern Ireland are a matter for the Northern Ireland Executive.